Suppr超能文献

用于靶向放射治疗的五价铼-188二巯基琥珀酸:合成及初步动物和人体研究。

Pentavalent rhenium-188 dimercaptosuccinic acid for targeted radiotherapy: synthesis and preliminary animal and human studies.

作者信息

Blower P J, Lam A S, O'Doherty M J, Kettle A G, Coakley A J, Knapp F F

机构信息

Nuclear Medicine Department, Kent and Canterbury Hospital, Canterbury, UK.

出版信息

Eur J Nucl Med. 1998 Jun;25(6):613-21. doi: 10.1007/s002590050263.

Abstract

Pentavalent rhenium-188 dimercaptosuccinic acid [188Re(V)DMSA] is a beta-emitting analogue of 99mTc(V)DMSA, a tracer that is taken up in a variety of tumours and bone metastases. The aim of this study was to develop the kit-based synthesis of the agent on a therapeutic scale, to assess its stability in vivo, and to obtain preliminary biodistribution and dosimetry estimates, prior to evaluation of its potential as a targeted radiotherapy agent. The organ distribution of 188Re in mice was determined 2 h after injection of 3 MBq 188Re(V)DMSA prepared from eluate from a 188W/188Re generator. Three patients with cancer of the prostate and three with cancer of the bronchus, all with bone metastases confirmed with a standard 99mTc-hydroxymethylene diphosphonate (99mTc-HDP) scan, were given 370 MBq 188Re(V)DMSA and imaged at 3 h and 24 h using the 155-keV gamma-photon (15%). Blood and urine samples were collected to determine clearance and to analyse the speciation of 188Re. Organ residence times were estimated from the scans, and used to estimate radiation doses using MIRDOSE 3. In mice, 188Re(V)DMSA was selective for bone and kidney. In patients, it showed selectivity for bone metastases (particularly those from prostate carcinoma) and kidney, but uptake in normal bone was not significantly greater than in surrounding soft tissues. Of the normal tissues the kidneys received the highest radiation dose (0.5-1.3 mGy/MBq). The images were strongly reminiscent of 99mTc(V)DMSA scans in similar patients. High-performance liquid chromatography analysis of blood and urine showed no evidence of 188Re in any chemical form other than 188Re(V)DMSA up to 24 h. In conclusion, 188Re(V)DMSA and its 186Re analogue warrant further clinical assessment as generator/kit-derived agents for treatment of painful bone metastases. These agents should also be assessed in medullary thyroid carcinoma and other soft tissue tumours which have been shown to accumulate 99mTc(V)DMSA.

摘要

五价铼-188二巯基丁二酸[188Re(V)DMSA]是99mTc(V)DMSA的一种发射β射线的类似物,99mTc(V)DMSA是一种可被多种肿瘤和骨转移灶摄取的示踪剂。本研究的目的是开发基于试剂盒的该制剂治疗规模的合成方法,评估其体内稳定性,并在评估其作为靶向放射治疗剂的潜力之前获得初步的生物分布和剂量学估计。在注射由188W/188Re发生器洗脱液制备的3 MBq 188Re(V)DMSA后2小时,测定小鼠体内188Re的器官分布。对3例前列腺癌患者和3例支气管癌患者(均经标准的99mTc-羟基亚甲基二膦酸盐(99mTc-HDP)扫描证实有骨转移)给予370 MBq 188Re(V)DMSA,并在3小时和24小时使用155 keVγ光子(15%)进行成像。采集血液和尿液样本以确定清除率并分析188Re的化学形态。从扫描图像估计器官停留时间,并使用MIRDOSE 3估计辐射剂量。在小鼠中,188Re(V)DMSA对骨和肾具有选择性。在患者中,它对骨转移灶(特别是前列腺癌转移灶)和肾具有选择性,但正常骨中的摄取量并不显著高于周围软组织。在正常组织中,肾脏接受的辐射剂量最高(0.5-1.3 mGy/MBq)。这些图像与类似患者的99mTc(V)DMSA扫描图像非常相似。血液和尿液的高效液相色谱分析显示,在24小时内除188Re(V)DMSA外,没有任何其他化学形式的188Re的证据。总之,188Re(V)DMSA及其186Re类似物作为发生器/试剂盒衍生的制剂用于治疗疼痛性骨转移值得进一步临床评估。这些制剂也应在甲状腺髓样癌和其他已显示可摄取99mTc(V)DMSA的软组织肿瘤中进行评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验